Annis Gardner Whiting Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13	Closed	-$1.71K	–	921
2026 Q1	$1.71K	Sell	13 -23	-64%	-$3.05K	﹤0.01%	1076
2025 Q4	$5.11K	Hold	36	–	–	﹤0.01%	872
2025 Q3	$5.05K	Hold	36	–	–	﹤0.01%	786
2025 Q2	$4.53K	Buy	+36	New	+$4.13K	﹤0.01%	864
2024 Q3	–	Sell	-156	Closed	-$21.5K	–	872
2024 Q2	$21.5K	Buy	156 +11	+8%	+$1.51K	0.01%	553
2024 Q1	$20K	Buy	+145	New	+$19.8K	0.01%	551

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's NBIX Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 13 shares — an estimated $1.71K sold.

Annis Gardner Whiting Capital Advisors first reported a position in NBIX in Q1 2024 and held it in 6 quarters. The position peaked at $21.5K in Q2 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Annis Gardner Whiting Capital Advisors reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
Annis Gardner Whiting Capital Advisors sold 13 Neurocrine Biosciences shares in Q2 2026, an estimated $1.71K.
Annis Gardner Whiting Capital Advisors first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 6 quarters.
Annis Gardner Whiting Capital Advisors's Neurocrine Biosciences position peaked at $21.5K in Q2 2024.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.